Plasma Proteomics Reveals Dysregulated Pathways Across the Spectrum <i>LMNA</i> Cardiomyopathy
Usman A. Tahir(Beth Israel Deaconess Medical Center), Neal K. Lakdawala(Brigham and Women's Hospital), Jacob L. Barber(Beth Israel Deaconess Medical Center), Laurie Farrell(Beth Israel Deaconess Medical Center), Joshen Patel(Brigham and Women's Hospital), Robert E. Gerszten(Broad Institute), Gaurav Tiwari(Beth Israel Deaconess Medical Center), Julia E. Marine(Brigham and Women's Hospital), Catherine G. Ireland(Brigham and Women's Hospital), Daniel Reichart(Brigham and Women's Hospital), Anisha Purohit(Brigham and Women's Hospital), Carolyn Y. Ho(Brigham and Women's Hospital), Darius Roy(Brigham and Women's Hospital), Christine E. Seidman(Brigham and Women's Hospital)
Cited by 1
Related Papers
Contemporary Definitions and Classification of the Cardiomyopathies
|Circulation|2006|3.4k
Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial
|The Lancet|2020|1.2k
Contribution of rare inherited and de novo variants in 2,871 congenital heart disease probands
|Nature Genetics|2017|927